

Dimpy P Shah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1926034/publications.pdf>

Version: 2024-02-01

68
papers

3,723
citations

218592

26
h-index

138417

58
g-index

70
all docs

70
docs citations

70
times ranked

7506
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	6.3	1,395
2	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	7.7	199
3	Management of Respiratory Viral Infections in Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies. Clinical Infectious Diseases, 2014, 59, S344-S351.	2.9	172
4	How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood, 2016, 128, 2624-2636.	0.6	140
5	Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. Journal of Antimicrobial Chemotherapy, 2013, 68, 1872-1880.	1.3	125
6	Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer. European Urology, 2018, 74, 575-582.	0.9	117
7	Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood, 2014, 123, 3263-3268.	0.6	110
8	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	7.7	108
9	Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Letters, 2016, 370, 358-364.	3.2	86
10	Outcomes of Influenza Infections in Hematopoietic Cell Transplant Recipients: Application of an Immunodeficiency Scoring Index. Biology of Blood and Marrow Transplantation, 2016, 22, 542-548.	2.0	68
11	Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. American Journal of Infection Control, 2016, 44, 1016-1021.	1.1	63
12	Utility of the Enzyme-Linked Immunospot Interferon- γ Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. Journal of Infectious Diseases, 2016, 213, 1701-1707.	1.9	63
13	Management of respiratory viral infections in hematopoietic cell transplant recipients. American Journal of Blood Research, 2012, 2, 203-18.	0.6	60
14	Human metapneumovirus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review. Cancer Letters, 2016, 379, 100-106.	3.2	56
15	An Adaptive Randomized Trial of an Intermittent Dosing Schedule of Aerosolized Ribavirin in Patients With Cancer and Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2012, 206, 1367-1371.	1.9	52
16	The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. Journal of Infectious Diseases, 2019, 219, 898-907.	1.9	52
17	Fecal colonization and infection with <i>Pseudomonas aeruginosa</i> in recipients of allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease, 2015, 17, 33-38.	0.7	48
18	Infection With Novel Respiratory Syncytial Virus Genotype Ontario (ON1) in Adult Hematopoietic Cell Transplant Recipients, Texas, 2011-2013. Journal of Infectious Diseases, 2015, 211, 582-589.	1.9	43

#	ARTICLE	IF	CITATIONS
19	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
20	Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. <i>Transplant Infectious Disease</i> , 2014, 16, 878-886.	0.7	41
21	Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. <i>Antiviral Research</i> , 2016, 134, 58-62.	1.9	37
22	Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 2365-2374.	2.9	36
23	Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz173.	0.4	32
24	Immune response to hepatitis B vaccination in drug using populations: A systematic review and meta-regression analysis. <i>Vaccine</i> , 2014, 32, 2265-2274.	1.7	31
25	Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2020, 126, 5124-5136.	2.0	30
26	Risk factors for mortality after respiratory syncytial virus lower respiratory tract infection in adults with hematologic malignancies. <i>Transplant Infectious Disease</i> , 2018, 20, e12994.	0.7	26
27	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
28	Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes. <i>Cancer</i> , 2017, 123, 2329-2337.	2.0	25
29	Influenza in patients with hematological malignancies: Experience at two comprehensive cancer centers. <i>Journal of Medical Virology</i> , 2018, 90, 50-60.	2.5	25
30	Characteristics and Outcomes of Pandemic 2009/H1N1 Versus Seasonal Influenza in Children With Cancer. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 373-378.	1.1	24
31	The CoVIDâ€TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVIDâ€19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2522-2532.	1.9	23
32	Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 800-809.	2.0	22
33	Long-Term Effectiveness of Accelerated Hepatitis B Vaccination Schedule in Drug Users. <i>American Journal of Public Health</i> , 2015, 105, e36-e43.	1.5	21
34	Cluster and Sporadic Cases of <i>Herbaspirillum</i> Species Infections in Patients With Cancer. <i>Clinical Infectious Diseases</i> , 2015, 60, 48-54.	2.9	21
35	Respiratory Syncytial Virus Infections in Children With Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e376-e381.	0.3	20
36	Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. <i>Antiviral Research</i> , 2016, 135, 91-96.	1.9	20

#	ARTICLE	IF	CITATIONS
37	Progression of the Radiologic Severity Index predicts mortality in patients with parainfluenza virus-associated lower respiratory infections. <i>PLoS ONE</i> , 2018, 13, e0197418.	1.1	19
38	Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2018, 217, 1247-1256.	1.9	17
39	Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa646.	0.4	17
40	Knowledge, Attitude, and Practices Regarding Occupational HIV Exposure and Protection among Health Care Workers in China. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 363-369.	0.6	15
41	Antigenic Fingerprinting of Respiratory Syncytial Virus (RSV)-Infected Hematopoietic Cell Transplant Recipients Reveals Importance of Mucosal Anti-RSV G Antibodies in Control of RSV Infection in Humans. <i>Journal of Infectious Diseases</i> , 2020, 221, 636-646.	1.9	14
42	Comparison of rectal swab, glove tip, and participant-collected stool techniques for gut microbiome sampling. <i>BMC Microbiology</i> , 2021, 21, 26.	1.3	14
43	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , 2021, 39, 895-896.	7.7	14
44	Utility of routine surveillance blood cultures in asymptomatic allogeneic hematopoietic stem cell transplant recipients with indwelling central venous catheters at a comprehensive cancer center. <i>American Journal of Infection Control</i> , 2014, 42, 1084-1088.	1.1	13
45	Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults. <i>Frontiers in Immunology</i> , 2019, 10, 706.	2.2	13
46	Demographics, socio-behavioral factors, and drug use patterns: What matters in spontaneous HCV clearance?. <i>Journal of Medical Virology</i> , 2012, 84, 235-241.	2.5	12
47	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	2.6	12
48	Comparison of long-term immunogenicity (23 y) of 10 µg and 20 µg doses of hepatitis B vaccine in healthy children. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1071-1076.	1.4	11
49	Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases. <i>Cancer Medicine</i> , 2019, 8, 3206-3215.	1.3	9
50	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
51	Differentially regulated gene expression associated with hepatitis C virus clearance. <i>Journal of General Virology</i> , 2013, 94, 534-542.	1.3	8
52	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac037.	0.4	8
53	Influenza Vaccination in Patients With Cancer: Factors Associated With Vaccination Practices for Patients and Their Household Members. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1239-1241.	1.0	7
54	Leukopenia and lack of ribavirin predict poor outcomes in patients with haematological malignancies and respiratory syncytial virus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3162-3169.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Receptor tyrosine kinase recepteur d'origine nantais as predictive marker for aggressive prostate cancer in African Americans. <i>Molecular Carcinogenesis</i> , 2019, 58, 854-861.	1.3	7
56	Antibody Response to the Furin Cleavable Twenty-Seven Amino Acid Peptide (p27) of the Fusion Protein in Respiratory Syncytial Virus (RSV) Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. <i>Vaccines</i> , 2020, 8, 192.	2.1	7
57	Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer. <i>IScience</i> , 2022, 25, 103699.	1.9	5
58	Challenges in Determining Genotypes for Pharmacogenetics in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 638-642.	1.2	3
59	The Economic and Clinical Burden of Respiratory Viral Infections in Hematopoietic Cell Transplant (HCT) Recipients: A Cost Comparison Study Across 19 Major Cancer Centers in the U. S. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S53.	2.0	2
60	An Open Label, Block-Randomized, Ribavirin Efficacy Trial for Management of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients: Clinical and Economic Implications. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S52-S53.	2.0	2
61	Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients. <i>Viruses</i> , 2021, 13, 991.	1.5	1
62	COVID-19 vaccine effectiveness in patients with hematologic malignancy. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	1
63	Reply to FÄtkenheuer et al. <i>Journal of Infectious Diseases</i> , 2013, 207, 1622-1623.	1.9	0
64	Reply to Robinson. <i>Journal of Infectious Diseases</i> , 2013, 208, 864-865.	1.9	0
65	The Utility of Interferon-Gamma Release Assays (IGRAs) for the Diagnosis of Mycobacterium Tuberculosis (Mtb) in Hematopoietic Cell Transplant (HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S175.	2.0	0
66	The Impact of Pre- and Week 4 Post-Transplant CMV-Specific Elispot Assay on CMV Reactivation and Survival in CMV-Seropositive Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S47-S48.	2.0	0
67	Drug-Resistant Cytomegalovirus Infections in Hematopoietic Cell Transplant Recipients: A Single Center Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S188-S189.	2.0	0
68	Outcomes of Resistant or Refractory CMV Infection in Recipients of Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S385-S386.	2.0	0